Orally administered β-glucan attenuates the Th2 response in a model of airway hypersensitivity
© The Author(s) 2016
Received: 11 May 2016
Accepted: 2 June 2016
Published: 21 June 2016
β-Glucan is a polysaccharide that can be extracted from fungal cell walls. Wellmune WGP®, a preparation of β-1,3/1,6-glucans, is a dietary supplement that has immunomodulating properties. Here we investigated the effect WGP had on a mouse model of asthma. OVA-induced asthma in mice is characterized by infiltration of eosinophils into the lung, production of Th2 cytokines and IgE. Daily oral administration of WGP (400 µg) significantly reduced the influx of eosinophils into the lungs of OVA-challenged mice compared to control mice. In addition, WGP inhibited pulmonary production of Th2 cytokines (IL-4, IL-5, IL-13), however serum IgE levels were unaffected by WGP treatment. These data indicate that WGP could potentially be useful as an oral supplement for some asthma patients, however, it would need to be combined with therapies that target other aspects of the disease such as IgE levels. As such, further studies that examine the potential of WGP in combination with other therapies should be explored.
Asthma is a chronic inflammatory airway disease that is caused by an allergic response in many cases. It affects 5–10 % of the population and is associated with significant morbidity and mortality (Barnes 2008). It is characterized by airway inflammation, airway hyperresponsiveness (AHR) and mucus production (Holgate 2012). Lung inflammation is caused by infiltration of eosinophils and T cells secreting Th2-cytokines (IL-4, IL-5, IL-13) into the lung. IL-4, IL-5 and IL-13 are important for IgE production, eosinophil recruitment and survival, mucus secretion and AHR development (Lloyd and Hessel 2010). In addition to eosinophilic Th2-associated asthma, other asthma phenotypes occur such as neutrophilic non-Th2 associated asthma. Currently the main treatment for asthma is corticosteroid administration, however some asthma phenotypes are refractory to corticosteroid therapy (Wenzel 2012). There is currently a significant level of research into the development of immunotherapies for asthma. These involve the targeting of IgE or cytokines such as IL-4, IL-5, IL-13. While many of these therapies are ineffective individually, researchers are currently examining the potential for combination therapies (Akdis 2012).
β-Glucan, a fungal cell wall extract, is marketed as a dietary supplement that can promote immune balance (Wichers 2009). β-Glucans are found in the cell walls of fungi, plants and some bacteria. β(1-3)- or β(1-6)-linked glucans are recognized by the Dectin-1 receptor. Dectin 1 is a type II transmembrane C-type lectin-like receptor, which recognizes both soluble and particulate β-glucans (Brown 2006; Brown et al. 2002, 2003). While Dectin-1 can bind both soluble and particulate β-glucans, only particulate β-glucans activate Dectin-1 signaling and responses (Goodridge et al. 2011). β-Glucan-induced signaling through Dectin-1 promotes Th1 and Th17 responses (Leibundgut-Landmann et al. 2008).
β-Glucan has been shown to exert beneficial therapeutic effects against various diseases. It has been shown to stimulate tumoricidal activity when co-administered with anti-tumor antibodies (Harada et al. 2003; Yan et al. 2005; Baran et al. 2007; Li et al. 2010; Hong et al. 2003, 2004). However, divergent results regarding the effect of β-glucan on respiratory health have been reported. It has been suggested that exposure to microbial products or mold can promote the development of asthma (Douwes 2005), while recent data suggest that β-glucans and other microbial signals may play a protective role against the development of asthma (Heederik and von Mutius 2012). Furthermore, β-glucan administration has been shown to prevent/improve symptoms of allergic rhinitis and upper respiratory tract infections (Fuller et al. 2012; Yamada et al. 2007). However, there is minimal data on the effect of β-glucan on asthma severity (Sarinho et al. 2009). In this study, we therefore examined the effect of oral administration of particulate β-glucan (WGP) in a mouse model of ovalbumin (OVA)-induced asthma. Here we demonstrate that oral administration of WGP reduces eosinophil influx and the production of Th2 cytokines (IL-4, IL-5, IL-13) in the lungs of OVA-challenged mice.
C57BL/6 mice were maintained under specific pathogen-free conditions at the NCI–Frederick, MD. Animal care was provided in accordance with the procedures in, “A Guide for the Care and Use of Laboratory Animals”. Ethical approval for the animal experiments detailed in this manuscript was received from the Institutional Animal Care and Use Committee at the NCI-Frederick.
Oral administration of PBS or WGP
Highly purified particulate β-glucan WGP was isolated from the cell wall of Saccharomyces cerevisiae (Biothera, Eagen, MN). The β-glucan preparation contained 81 % β-1,3/1,6-glucan, 0.5 % mannose, <3.5 % protein and <10 % fat. Mice were treated daily with 25–100 μl PBS containing 400 μg Wellmune WGP from Biothera or PBS alone by oral gavage or alternatively by feeding by pipet as needed. Treatment was started 7 days prior to beginning OVA sensitization, and was continued for the duration of the study.
Sensitization and airway challenge
Bronchoalveolar lavage fluid (BALF) collection
Prior to BALF collection, mice were given a ketamine/xylazine mixture to induce deep anesthesia and analgesia. Once sedated, as determined by toe-pinch, the thoracic cavity was opened to reveal the lungs and trachea. Using a cannula and leur lock syringe, the lungs were expanded using 1 mL of PBS and recollected as BALF, for a total of 2–3 washes. The mice were euthanized by heart perfusion using 5–10 mL PBS, and the lungs and other tissues were collected.
BALF cytospin and differential cell count analysis
Cells from the BAL were collected, and the BALF was saved for cytokine analysis. Red blood cell lysis was performed if necessary, cells were washed in PBS, and then counted using a hemacytometer. 100 μL containing approximately 5 × 104 cells were loaded onto a cytospin column and centrifuged onto a microscope slide. Following Diffquick cell staining, differential cell counts were blindly assessed for each sample, counting at least 500 cells per slide.
BALF was clarified by centrifugation, aliquoted and stored at −80 °C for later analysis. Cytokine levels were measured in BALF using ELISA kits from eBioscience (San Diego, CA) and R&D Systems (Minneapolis, MN). Myeloperoxidase (MPO) activity in BALF samples was measured using the Myeloperoxidase activity fluorometric assay kit from BioVision (Mountain View, CA). Eosinophil peroxidase (EPO) in BALF samples was measured using an Eosinophil peroxidase ELISA kit (Cusabio Biotech, Wuhan, China). Soluble collagen levels in BALF were measured by adding 200 µL of 0.1 % Direct Red 80 in picric acid (Sigma Aldrich, St. Louis, MO) to 50 µL of lavage fluid and incubating for 60 min at 37 °C. The samples were centrifuged and the pellet was washed with 100 % ethanol. The pellet was resuspended in 200 µl 0.5 M NaOH, incubated for 30 min at 37 °C and the absorbance was read at 540 nm.
Lung and spleen cell isolation and flow cytometry
Lung cells were isolated by collagenase and DNase digestion (Sigma Aldrich). Splenocytes were mashed through 100 µm nylon cell strainers and erythrocytes were lysed in ACK buffer. Lung cells were washed with Hank’s Balanced Salt Solution (HBSS) and splenocytes were washed with PBS. Lung cells and splenocytes were pre-incubated with the 2.4 G2 antibody to block Fc receptor binding, followed by incubation with various cell surface Abs: CD3 (17-A2), NK1.1 (PK136), B220 (RA3-6B2), F4/80 (BM8), MHCII (M5/114.15.2), (eBioscience, San Diego, CA), Siglec F (E50-2440), CD11c (N418), CD11b (M1/70), Gr-1 (RB6-8C5) and Ly6G (1A8) (BD Biosciences, San Jose, CA). Cells were fixed with BD Cytofix and analysed on BD LSRII.
Blood cell measurement
Blood samples were taken prior to the start of the experiment, and again on the day of harvest. Cell composition was measured using the Hemavet 950 automated blood cell counter, (Drew Scientific, Waterbury, CT), according to the manufacturer’s protocol.
RNA isolation and analysis
A portion of the lung was excised and placed in Trizol for RNA isolation. The lung tissue in Trizol was homogenized using a mini-beadbeater. RNA was extracted using the Trizol protocol and purified using the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized using Taqman Reverse Transcription Reagents for RT-PCR (Applied Biosystems). Quantitative RT-PCR was performed using ABI Taqman Primer and Probe sets and normalization was performed against Hprt1.
Measurement of IgE
Total IgE levels in serum were measured using the IgE ELISA from BD Biosciences (San Jose, CA). OVA specific IgE was measured using the Legend Max Mouse OVA Specific IgE ELISA kit from Biolegend (San Diego, CA).
The lungs were placed in 10 % formalin, embedded in paraffin wax blocks and 4 μm sections cut and stained for either haematoxylin and eosin (H&E) or periodic acid Schiff (PAS) to determine airway inflammation and goblet cell metaplasia respectively. All histological sections were blindly assessed by a pathologist and the total number of bronchiole and perivascular aggregates of inflammatory cells were counted in each lung. Mucous cell metaplasia within the bronchioles was compared to normal control tissue and graded as 0 = no difference, 1 = scattered mucous cells, 2 = aggregates of mucous cells, 3 = monolayer layer of mucous cells and 4 = multilayered mucous cells.
Data are expressed as mean ± SEM. Statistical significance was determined using Student’s t test or 1-way ANOVA followed by Bonferroni’s post-test. Statistical significance was set at *p < 0.05, **p < 0.01, ***p < 0.001.
Systemic impact of oral WGP administration
WGP reduces total BALF cell numbers and eosinophil accumulation
WGP modulates lung cellular composition
WGP does not affect OVA-induced histopathological changes in the lung
WGP reduces Th2 cytokine levels in the lung
Several natural products are advertised as immunotherapeutics and many claims are made about their effects on a wide range of diseases including asthma. Here we tested the effect of Wellmune WGP β-1,3/1,6-glucan during a mouse model of OVA-induced asthma. We demonstrated that daily oral administration of WGP reduces eosinophil influx into the lungs and the production of Th2 cytokines (IL-4, IL-5, IL-13) compared to control mice. Serum IgE levels and OVA-specific IgE levels were unaffected by administration of WGP. Together these data indicate that WGP administration would not, in and of itself, be sufficient as a single treatment for asthma, however as it targets the critical initiator step in asthma immune responses (or similar) it may prove useful as a combination therapy.
Asthma is a heterogeneous disease and patients present with various distinct clinical phenotypes. Different mouse models are being developed to model the different phenotypes found in asthma patients (Lloyd and Hessel 2010; Nials and Uddin 2008; Lloyd 2007). The OVA-induced airway hypersensitivity model of asthma used here results in eosinophilic inflammation in the lung, pulmonary production of Th2 cytokines (IL-4, IL-5 and IL-13) and serum IgE production (Lloyd and Hessel 2010; Lloyd 2007). The role of Th2 cells in patients with asthma is well established and T cell activation has been related to asthma severity in some studies (Walker et al. 1991; Robinson et al. 1993). IL-4, IL-5 and IL-13 have been shown to have roles in IgE production, eosinophil survival, AHR development and tissue remodeling (Finkelman et al. 2010). Here we observed a significant reduction in production of Th2 cytokines and eosinophil influx with WGP administration, although this does not reach a threshold to see histological differences. Additionally, IgE production and soluble collagen levels were unaffected by the administration of WGP. Therefore, while other factors in addition to Th2 cells/cytokines are involved in the pathogenesis of asthma (Lloyd and Hessel 2010), it appears that WGP is specific in targeting the production of IL-4, IL-5, IL-13 and resulting eosinophilia in this model. This targeted effect is important as local production of these cytokines is associated with AHR development and downstream complications. While our results indicate no impact on collagen-deposition or lung pathology, these studies may only represent an acute effect. It is possible that with long-term WGP-administration after asthma is established or in combination with other therapies, the continued decrease in Th2 responses could protect against damaging inflammation and fibrosis in the lung.
β-Glucan has immunomodulating properties and it has been shown to exert beneficial therapeutic effects against various diseases including allergic diseases. One study demonstrated that administration of WGP to ragweed allergy sufferers reduced allergy symptoms however similar to our findings it had no effect on serum IgE levels (Talbott et al. 2013). Another study showed that β-glucan administration to subjects with seasonal allergic rhinitis resulted in reduced IL-4 and IL-5 levels (Kirmaz et al. 2005). Our data demonstrating reduced IL-4 and IL-5 levels in WGP-treated mice in an OVA-induced asthma model is in agreement with these findings. In addition a study demonstrated a reduction in asthmatic symptoms following β-glucan administration and increased IL-10 levels (Sarinho et al. 2009).
Daily oral administration of WGP (400 µg) significantly reduced pulmonary eosinophil influx and production of Th2 cytokines (IL-4, IL-5, IL-13), however serum IgE levels were unaffected by WGP treatment in an OVA-induced asthma model. Our findings suggest that WGP could be used to target some aspects of asthma (Th2 cytokines and eosinophilia). While WGP alone would not be sufficient to treat asthma, it could be used in combination with other therapies that target different aspects of the disease such as IgE levels. As WGP is an oral supplement, it could be considerably more cost effective and may have fewer side effects than immunotherapies. In addition, as IL-4, IL-5 and IL-13 are all reduced in response to WGP, the broader effects of WGP could be more beneficial than immunotherapies that target one specific cytokine such as IL-4 or IL-5. Further studies would need to be conducted to determine the effect of WGP in combination with other therapies for specific subsets of asthma patients.
ARB carried out the experiments, participated in the study design and helped to draft the manuscript. LQ, AVJ, GMO and KB carried out the experiments and participated in data analysis. DWM participated in the design of the project. SJO designed the project, carried out the experiments and drafted the manuscript. All authors read and approved the final manuscript.
This research was supported in part by the NIH Office of Dietary Supplements and in part by the Intramural Research Program of the NIH, National Cancer Institute. SJO is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 099953/Z/12/Z). We would like to thank Megan Karwan, Kelli Czarra and Grace Williams for animal care for this project.
The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
The authors have no competing financial interests.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Akdis CA (2012) Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 18:736–749View ArticleGoogle Scholar
- Baran J, Allendorf DJ, Hong F, Ross GD (2007) Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice. Folia Histochem Cytobiol 45:107–114Google Scholar
- Barnes PJ (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183–192View ArticleGoogle Scholar
- Brown GD (2006) Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 6:33–43View ArticleGoogle Scholar
- Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S (2002) Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 196:407–412View ArticleGoogle Scholar
- Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S (2003) Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 197:1119–1124View ArticleGoogle Scholar
- Douwes J (2005) (1–>3)-Beta-d-glucans and respiratory health: a review of the scientific evidence. Indoor Air 15:160–169View ArticleGoogle Scholar
- Finkelman FD, Hogan SP, Hershey GK, Rothenberg ME, Wills-Karp M (2010) Importance of cytokines in murine allergic airway disease and human asthma. J Immunol 184:1663–1674View ArticleGoogle Scholar
- Fuller R, Butt H, Noakes PS, Kenyon J, Yam TS, Calder PC (2012) Influence of yeast-derived 1,3/1,6 glucopolysaccharide on circulating cytokines and chemokines with respect to upper respiratory tract infections. Nutrition 28:665–669View ArticleGoogle Scholar
- Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, Danielson ME, Weiss A, Vasilakos JP, Underhill DM (2011) Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’. Nature 472:471–475View ArticleGoogle Scholar
- Harada N, Kodama N, Nanba H (2003) Relationship between dendritic cells and the D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice. Cancer Lett 192:181–187View ArticleGoogle Scholar
- Heederik D, von Mutius E (2012) Does diversity of environmental microbial exposure matter for the occurrence of allergy and asthma? J Allergy Clin Immunol 130:44–50View ArticleGoogle Scholar
- Holgate ST (2012) Innate and adaptive immune responses in asthma. Nat Med 18:673–683View ArticleGoogle Scholar
- Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, Ross GD (2003) Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 63:9023–9031Google Scholar
- Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD (2004) Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 173:797–806View ArticleGoogle Scholar
- Kirmaz C, Bayrak P, Yilmaz O, Yuksel H (2005) Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study. Eur Cytokine Netw 16:128–134Google Scholar
- Leibundgut-Landmann S, Osorio F, Brown GD, Reis e Sousa C (2008) Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 112:4971–4980View ArticleGoogle Scholar
- Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J (2010) Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res 16:5153–5164View ArticleGoogle Scholar
- Lloyd CM (2007) Building better mouse models of asthma. Curr Allergy Asthma Rep 7:231–236View ArticleGoogle Scholar
- Lloyd CM, Hessel EM (2010) Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol 10:838–848View ArticleGoogle Scholar
- Monick MM, Mallampalli RK, Carter AB, Flaherty DM, McCoy D, Robeff PK, Peterson MW, Hunninghake GW (2001) Ceramide regulates lipopolysaccharide-induced phosphatidylinositol 3-kinase and Akt activity in human alveolar macrophages. J Immunol 167:5977–5985View ArticleGoogle Scholar
- Nials AT, Uddin S (2008) Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech 1:213–220View ArticleGoogle Scholar
- Robinson DS, Bentley AM, Hartnell A, Kay AB, Durham SR (1993) Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax 48:26–32View ArticleGoogle Scholar
- Sarinho E, Medeiros D, Schor D, Rego Silva A, Sales V, Motta ME, Costa A, Azoubel A, Rizzo JA (2009) Production of interleukin-10 in asthmatic children after Beta-1-3-glucan. Allergol Immunopathol (Madr) 37:188–192View ArticleGoogle Scholar
- Talbott SM, Talbott JA, Talbott TL, Dingler E (2013) Beta-Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers. Food Sci Nutr 1:90–101View ArticleGoogle Scholar
- Walker C, Kaegi MK, Braun P, Blaser K (1991) Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 88:935–942View ArticleGoogle Scholar
- Wenzel SE (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18:716–725View ArticleGoogle Scholar
- Wichers H (2009) Immunomodulation by food: promising concept for mitigating allergic disease? Anal Bioanal Chem 395:37–45View ArticleGoogle Scholar
- Yamada J, Hamuro J, Hatanaka H, Hamabata K, Kinoshita S (2007) Alleviation of seasonal allergic symptoms with superfine beta-1,3-glucan: a randomized study. J Allergy Clin Immunol 119:1119–1126View ArticleGoogle Scholar
- Yamauchi E, Shoji S, Nishihara M, Shimoda T, Nishima S (2008) Contribution of lung fibroblast migration in the fibrotic process of airway remodeling in asthma. Allergol Int 57:73–78View ArticleGoogle Scholar
- Yan J, Allendorf DJ, Brandley B (2005) Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther 5:691–702View ArticleGoogle Scholar